We have noticed that the trough level of blood concentration of cyclosporin A (CyA) tends to be lower in patients receiving long-term oral levothyroxine (LTX) than in patients not receiving LTX. We conˆrmed this clinical observation in experiments using Wistar rats orally given LTX (8 mg W kg) or saline (control) for 3 weeks, followed by CyA (10 mg W kg). The LTX treatment had little eŠect on the blood concentrations of CyA after i.v. administration, whereas they were decreased signiˆcantly after p.o. administration. After p.o. administration, the value of the area under the blood concentration-time curve from 0 to 24 hr and the bioavailability of CyA in the LTX group were decreased to only about onefth and a quarter of those in the control group, respectively. After treatment with LTX, the expression levels of mdr1a, mdr1b and CYP3A2 mRNAs in the duodenum were markedly increased to about twice the control, but in jejunum, ileum and liver the expression levels were little changed. Theseˆndings suggest that the absorption of CyA, which occurs mainly from the upper intestine, is reduced as a result of eOEux transport via P-glycoprotein induced by LTX. In conclusion, careful monitoring of CyA levels is required in the event of LTX administration to patients receiving immunotherapy with CyA.
Introduction
It is well established that the induction of gene expression by dexamethasone (DEX), rifampicin, phenobarbital, and various other drugs is mediated by nuclear receptors such as pregnane X receptor (PXR) and constitutive androstane receptor (CAR). [1] [2] [3] [4] We previously reported that the decrease in the blood concentrations of cyclosporin A (CyA) and FK506 caused by high-dose steroid therapy is a consequence of the induction of P-glycoprotein (P-gp) and CYP3A in the liver and intestine, and these changes were reversed within 2 weeks after the cessation of steroid therapy. 5, 6) Hormones also regulate transcription factors by binding to nuclear receptors, so it is possible that drug disposition kinetics can be altered by the induction of transporter and CYP genes in patients with hormonerelated disease or patients receiving long-term hormone therapy.
There are some reports indicating that patients with hyperthyroidism or heart failure might require largerthan-normal doses of digitalis to regulate their heart rate. 7, 8) Siegmund et al. 9) found that the expression of P-glycoprotein (P-gp) was increased in duodenum after oral administration of levothyroxine (LTX, 200 mg W day) for 17 days in healthy volunteers, and the half life of talinolol, a substrate of P-glycoprotein, was slightly decreased. Recently, we have noted that the blood CyA concentration tends to be decreased in patients receiving oral immunotherapy with CyA in combination with LTX, in comparison with similar patients not receiving LTX (Fig. 1) . In this study, we attempted to clarify the mechanism of the drug interaction between CyA and LTX, by means of animal experiments.
Materials and Methods
Chemicals: Thyradin S } tablets (levothyroxine sodium, LTX) and Sandimmun } injection (cyclosporin A, CyA) were purchased from Teikoku Hormone Co. Ltd. (Tokyo, Japan) and Novartis Pharma Co. Ltd. (Tokyo, Japan), respectively. Oligonucleotide primers were custom-synthesized by Amersham Pharmacia Biotech (UK). Primary antibody (mouse anti-P-glycoprotein C219) and secondary antibody (anti-mouse IgG HRP-linked antibody) for P-gp were purchased from DAKO Co., Ltd. (CA, USA) and Cell Signaling (MA, USA), respectively. Primary antibody (goat anti-rat CYP3A2 antibody) and secondary antibody (peroxidase-labeled anti-goat IgG) for CYP3A2 were purchased from Daiichi Pure Chemicals Co., Ltd. (Tokyo, Japan) and Vector Laboratories, Inc. (CA, USA), respectively. Other reagents were purchased from Sigma Co. (MO, USA).
Animal Experiments: All animal experiments were performed in accordance with the guidelines of the Institutional Animal Care and Use Committee of the University of Kanazawa.
Male 7-week-old Wistar rats (Japan SLC Co., Hamamatsu, Japan) were orally administered a suspension of LTX (8 mg W kg W day), prepared by grinding Thyradin S } tablets in distilled water, daily for 3 weeks. The control rats received distilled water alone. A 100 mL aliquot of CyA (10 mg W kg) was injected via the femoral vein at 24 h after the last treatment with LTX. Blood samples (200 mL each) were collected at designated time intervals from the jugular vein of untreated rats and LTX-treated rats under light ether anaesthesia.
Measurement of blood concentration of CyA: Blood concentration of CyA was measured with a TDx analyzer using a commercial kit according to the manufacturer's instructions (Dainabot Co. Ltd., Tokyo, Japan). The TDx assay is a ‰uorescence polarization immunoassay (FPIA) reagent system for the measurement of CyA.
10) The measurement range of blood concentration was 25-1500 ng W mL. The crossreactivities with the metabolites of CyA were 19.4z for M1 and less than 5z for other metabolites.
Measurement of plasma concentrations of T3, T4 and TSH: Blood samples were collected under light ether anesthesia from the jugular vein of rats before the LTX treatment and at 24 h after the 3-week LTX treatment. Serum was separated by centrifugation and stored at -309 C. Measurements of triiodothyronine (T3), thyroxine (T4) and thyroid stimulating hormone (TSH) were conducted by SRL Co. Ltd. (Tokyo, Japan).
Reverse Transcriptase-polymerase
Chain Reaction (RT-PCR) Assay: Total RNA was isolated from the liver and intestine by using an Isogen Kit (Wako, Osaka). Synthesis of cDNA from the isolated total RNA was carried out using RNase H-reverse transcriptase (Invitrogen Co., Tokyo, Japan). Reverse transcription (RT) reactions were carried out in 40 mM KCl, 50 mM Tris-HCl (pH 8.3), 6 mM MgCl2, 1 mM dithiothreitol, 1 mM each of dATP, dCTP, dGTP, and dTTP, 10 units of RNase inhibitor (Promega, Madison, WI), 100 pmol of random hexamer, total RNA and 200 units of the Moloney murine leukemia virus reverse transcriptase (Invitrogen Co.) in aˆnal volume of 22 mL (1 mg W mL) at 379 C for 60 min. Polymerase chain reaction (PCR) was carried out in aˆnal volume of 20 mL, containing 1 mL of RT reaction mixture, 50 mM KCl, 20 mM Tris-HCl (pH 8.3), 2.5 mM MgCl2, 0.2 mM each of dATP, dCTP, dGTP, and dTTP, 10 mM each of the mixed oligonucleotide primers, and 1 unit of Taq DNA polymerase (Invitrogen Co.). Primers were used for rat mdr1a (511 bp), 11) rat mdr1b (451 bp), 11) rat CYP3A2 (252 bp), 12) and rat b-actin (456 bp), 13) respectively. Each cycle consisted of 30 sec at 949 C, 60 sec at 609 C, and 75 sec at 729 C for mdr1a and mdr1b, 30 sec at 949 C, 60 sec at 559 C, and 75 sec at 729 C for CYP3A2, and 30 sec at 949 C, 60 sec at 589 C, and 75 sec at 729 C for b-actin. The PCR reaction was run for 26 cycles for mdr1a, mdr1b and CYP3A2, and for 22 cycles for b-actin.
Preparation of plasma membrane fraction and microsomes: For the preparation of plasma membrane fraction, the liver was homogenized in 10 mM Tris-HCl buŠer (pH 7.5) containing 2 mM CaCl2 at 49 C. The homogenate was centrifuged at 3,500×g for 10 min, and the supernatant was then centrifuged at 15,000×g for 30 min. The pellet was washed, resuspended in 50 mM Tris-HCl buŠer (pH 7.2), and was twice centrifuged at 10,000×g for 5 min, and stored at -809 C until use.
The intestine was quickly removed and washed with Each value represents the mean±SD (n＝4). ** Signiˆcantly diŠerent from before treatment at pº0.01. ice-cold isotonic saline containing 1 mM phenylmethylsulfonyl ‰uoride (PMSF). Mucosa was scraped on ice with a slide glass and homogenized in a buŠer containing 250 mM sucrose, 50 mM Tris-HCl (pH 7.4), 1 mM PMSF. The homogenate was centrifuged at 3,000×g for 10 min, and the supernatant was again centrifuged at 15,000×g for 30 min. The pellet was resuspended in 0.5 mL of a buŠer containing 50 mM mannitol, 50 mM Tris-HCl (pH 7.4), 1 mM PMSF, and stored at -809 C until use.
For the preparation of microsomes fraction, the intestine was quickly removed and washed with buŠer containing 2 mM HEPES, 0.9z NaCl and 0.5 mM phenylmethylsulfonyl ‰uoride (PMSF). Mucosa was scraped on ice with a slide glass and homogenized in a buŠer containing 300 mM mannitol, 5 mM EDTA, 5 mM HEPES and 1 mM PMSF (pH 7.1). The homogenate was centrifuged at 10,000×g for 20 min, and the supernatant was centrifuged at 105,000×g for 60 min. The pellet was added same buŠer and the homogenate was again centrifuged at 105,000×g for 60 min, and stored at -809 C until use.
Rat liver microsomes were prepared as described previously 14) and stored at -809 C until use. Protein concentrations were measured according to the method of Lowry et al.
15)
SDS-PAGE and immunoblotting: SDS-PAGE and immunoblotting with peroxidase W antiperoxidase staining of the plasma membrane for P-gp and of the microsomes for CYP3A2 were carried out essentially as described by Laemmli 16) and Guengerich et al. 17) The sample protein of liver and intestine was used 4 or 200 mg for CYP3A2, and 30 or 300 mg for P-gp, respectively. The sample protein was electrophoresed on 10z sodium dodecyl sulfate-polyacrylamide gel and transferred onto nitrocellulose membraneˆlters (Schleicher & Schuell, Dassel, Germany). After having been blocked with 5z skim milk, theˆlters were incubated overnight with primary antibody, C219 and goat anti-rat CYP3A2 antibody, and for 1 h with secondary antibody, anti-mouse IgG HRP-linked antibody and peroxidase-labeled anti-goat IgG. Thereafter, the sample was extensively washed with phosphate-buŠered saline. The immunopositive band was detected by means of a light-emitting nonradioactive detection system (Amersham International plc, Little Chalfont, Buckinghamshire, UK) with Kodak X-Omat Rˆlm (Eastman Kodak Co., Rochester, NY).
Data Analysis: The pharmacokinetic parameters were estimated according to model-independent moment analysis as described by Yamaoka et al.
18)
Where appropriate, data were analyzed using the Mann-Whitney U test to compare the unpaired mean values of two sets of data (Fig. 1) . Other data were analyzed using Student's t test to compare the unpaired mean values of two sets of data (Fig. 4, Tables 1, 2 ). The number of determinations is noted in each table and gure. A value of Pº0.05 or 0.01 was taken to indicate a signiˆcant diŠerence. The electrophoresis results were analyzed by using NIH Image software.
Case Report
In 40 patients who had received immunotherapy with oral administration of Neoral } capsule (CyA, Novartis Pharma Co. Ltd., Tokyo, Japan), (twice a day, daily, for over one year), the blood concentrations of CyA were measured at the trough level. The blood samples were collected from 30 patients without LTX treatment (16 men and 14 women) aged 4 to 61 (32.6±16.9, mean ±SD) years and weighing 17 to 75 (51.4±13.3) kg, and from 10 patients with LTX treatment (100 mg W day, p.o., once a day, daily, over 3 months), (6 men and 4 women) aged 6 to 58 (25.2±16.5) years and weighing 12 to 70 (44.6±16.0) kg. The patients were selected for study because their hepatic and renal functions were at normal condition and they were not administered a drug which Fig. 2 . Blood concentration-time courses of CyA after i.v. or p.o. administration of CyA (10 mg W kg) at 24 h after the last treatment in the control rats and in rats orally treated daily for 3 weeks with LTX (8 mg W kg W day). Each point and bar represents the mean±SE of four rats. Fig. 3 . The expression of mdr1a, mdr1b and CYP3A2 mRNAs in duodenum, jejunum, ileum and liver of control and LTX-treated rats. Rats were orally given LTX (8 mg W kg W day) for 3 weeks. Lanes 1-3, control; Lanes 4-7; at 24 h after the last administration of LTX. may in‰uence on the disposition kinetics of CyA. Figure 1 shows the relationship between the dose and blood concentration of CyA in 40 patients with or without LTX treatment. The blood concentrations of CyA represented the mean value (n＝2-6) in every patients collected for 6 months. The correlation coe‹cients were r＝0.669 in the non-LTX group and r＝0.719 in the LTX group, but the blood concentrations of CyA in the LTX group were signiˆcantly lower than those in the non-LTX group (pº0.05).
Experimental Results
Plasma concentrations of T3, T4 and TSH: Table 1 shows the plasma concentrations of T3, T4 and TSH before and at 24 h after administration of LTX (8 mg W kg W day, p.o.) for 3 weeks. The plasma concentrations of T4 were signiˆcantly increased, but the values of T3 and TSH were little changed.
Pharmacokinetics of CyA after LTX treatment in rats: The blood concentration-time courses of CyA after i.v. or p.o. administration of CyA (10 mg W kg) in control rats and in rats treated with LTX (8 mg W kg W day, p.o.) for 3 weeks are shown in Fig. 2 . The blood concentrations of CyA after i.v. administration in the LTX group tended to be decreased compared with those of the control group, but the diŠerence was not signiˆcant. After p.o. administration, the blood concentrations of CyA in the LTX group were signiˆcantly lower than those of the control group.
The pharmacokinetic parameters of CyA in the two groups are listed in Table 2 . There were no signiˆcant diŠerences between the two groups after i.v. administration of CyA. But, after p.o. administration the value of the area under the blood concentration-time curve from 0 to 24 hr (AUC) of the LTX group was only about onefth of that of the control group (pº0.01). The oral bioavailability of CyA of the LTX group was decreased to about a quarter of that in the control group.
RT-PCR Analysis of mdr1a, mdr1b and CYP3A2 mRNAs in the tissues: Figures 3 and 4 show the eŠect of LTX at 24 h after the last treatment (8 mg W kg W day, p.o., for 3 weeks) on the expression of mdr1a, mdr1b and CYP3A2 mRNAs in the duodenum, jejunum, ileum and liver. The expression levels of mdr1a and mdr1b mRNAs in small intestine of the control rats were greatest in the ileum, followed by jejunum and duodenum, but that of CYP3A2 mRNA was not diŠerent among the tissues. On the other hand, following treatment with LTX, the expression of mdr1a and mdr1b mRNAs was increased more in tissues initially showing lower expression, and consequently, expression in the duodenum was increased to about 2-fold of the untreated control.
Western blot analysis of P-gp and CYP3A2 in the Fig. 4 . EŠect of LTX on the expression of mdr1a, mdr1b and CYP3A2 mRNAs. The data represent the relative expression of the mRNAs given by dividing mRNA W b-actin ratios in the LTX-treated group by that in the control group. Each column and bar represents the mean±SD of four rats. *Signiˆcantly diŠerent from the control group at pº0.05. Duodenum, ; jejunum, ; ileum, □; liver, Fig. 5 . Western blot analysis of P-gp and CYP3A2 in the duodenum, jejunum, ileum and liver of control and LTX-treated rats. a) Rats were orally given LTX (8 mg W kg W day) for 3 weeks. Lane 1, control; Lane 2, at 24 h after the last administration of LTX. b) Relative expression of P-gp and CYP3A2 proteins. Each column and bar represents the mean±SD of four rats. * Signiˆcantly diŠerent from the control group at pº0.05. Duodenum, ; jejunum, ; ileum, □; liver, tissues: Figure 5 shows the protein levels of P-gp and CYP3A2 in duodenum, jejunum, ileum and liver at 24 h after the last LTX treatment (8 mg W kg W day, p.o., for 3 weeks). The protein level of P-gp in duodenum was elevated to about 2-fold of the control by LTX treatment, but the levels in other tissues showed no marked change. The protein level of CYA3A2 showed little change in all of the tissues.
Discussion
We had noticed that the trough blood concentrations of CyA tended to be lower in patients receiving longterm oral LTX treatment than in those not receiving LTX. Therefore, in this study, we attempted to clarify the mechanism of the decrease of blood CyA concentration in patients receiving CyA immunotherapy in combination with LTX, by means of animal experiments.
First, we examined the in‰uence of LTX on the expression of mdr1a, mdr1b and CYP3A2 mRNAs in small intestine and liver of rats. The expression of mdr1a and mdr1b mRNAs in the control group was in the order of ileumÀjejunumÀduodenum. The 3-week administration of LTX increased the expression of these mRNAs by about 2-fold speciˆcally in the duodenum, where the expression was initially lowest (Fig. 4) . It has also been reported that the expression of P-gp is induced in duodenum of LTX-treated volunteers. 9) These results may re‰ect the fact that the duodenum is the initial site of exposure after the p.o. administration of LTX, although CYP3A2 mRNA expression was not diŠerent among the tissues. We conˆrmed that the changes of protein expression of P-gp and CYP3A2 corresponded to the extents of induction of the mRNAs (Fig. 5) . Mitin et al. 19) reported that P-gp, but not CYP3A2, is induced by LTX (100 mM) in human colon carcinoma cells (LS180 and Caco-2) in vitro, and the induction is mediated by thyroid hormone receptor (TR) rather than PXR. Our results are consistent with this. Thus, it seems that LTX more strongly aŠects tissues that exhibit a lower basal gene expression by acting via TR, although this requires conˆrmation.
Siegmund et al. 9) reported that, although the expression of P-gp in duodenum was increased 3.8-fold by LTX treatment, the change in P-gp expression was associated with only minor alterations in the half-life of talinolol after both oral and intravenous administration. However, in our case, the increase of about 2-fold in the duodenal expression of P-gp induced by LTX greatly decreased the bioavailability of CyA to about a quarter of that in the control rats ( Table 2) . It has been reported that CyA is absorbed predominantly from the upper small intestine. 20) Because CyA is a good substrate of P-gp, its absorption is likely to be highly vulnerable to modulation of P-gp expression on the brush border membranes of the upper small intestine. Previously, we showed that the bioavailability of CyA greatly decreased from 22.2z to 6.8z by the DEX treatment (1 mg W kg W day) for 7 days, probably due to the markedly enhanced level of P-gp expression in the intestine 5) . But, in this study, even though the induction of P-gp expression in the duodenum by the LTX treatment was smaller compared with that in the case of the previous DEX treatment, the extent of decrease in CyA bioavailability was roughly the same. Theseˆndings may indicate that CyA bioavailability is greatly in‰uenced independent of the extent of induction of P-gp, because the expression of P-gp in duodenum is initially very low and CyA is mainly absorbed from the upper small intestine.
On the other hand, in the case of i.v. administration of CyA, the disposition kinetics of CyA was little changed by LTX treatment (LTX 8 mg W kg W day, p.o., for 3 weeks), presumably because the expression of mdr1 and CYP3A mRNAs in the liver did not change almost. Moreover, Matsubara et al. 21) reported that the mRNAs and proteins of CYP3A1 and CYP3A2 were induced in the rat liver after the DEX treatment (100 mg W kg W day) for 3 days, while those of CYP3A62 and CYP3A9 were induced in the intestine. In this study, although we did not evaluate the eŠect of LTX treatment on the expression of CYP3A62 and CYP3A9, we believe that the in‰uence of LTX treatment on these proteins was slight, if any, because the CLtot value of CyA after the i.v. administration of CyA was little changed by LTX treatment.
Taken together, we think that the disposition of CyA is in‰uenced by the induction of P-gp only, but not of CYP. However, interaction between CyA and LTX might well occur when these proteins are induced under certain conditions, depending on dosage, physiology, and other factors. We previously reported that the low-dose DEX treatment (1 mg W kg) induced only the expression of P-gp in the liver and intestine, while the high-dose DEX-treatment (75 mg W kg) induced expressions of both P-gp and CYP3A. 5, 6) Therefore, the eŠect of LTX treatment may also be dose-dependent.
In conclusion, our results indicate that the decrease of blood CyA concentration in patients receiving CyA together with LTX for hypothyroidism is due to the induction of P-gp expression in the small intestine by LTX. Therefore, blood concentration of drugs that are substrates of P-gp, such as CyA, should be carefully monitored in patients when these drugs are administered in combination with LTX.
